论文部分内容阅读
目的:评价布地奈德福莫特罗粉吸入治疗肺癌合并慢性阻塞性肺气肿(COPD)患者的临床疗效及对患者生活质量的影响。方法:选择2015年1月~2016年12月我院收治的肺癌合并COPD患者68例,按照随机数字表法分为治疗组和对照组,每组34例。对照组给予常规对症治疗,治疗组在对照组的基础上给予布地奈德福莫特罗粉吸入剂治疗,2次/天,规律治疗3个月。比较两组患者治疗前后用力肺活量占预测值的百分比(FVC%)、第一秒用力呼气量占预测值的百分比(FEV1%)水平、COPD评估测试及圣乔治呼吸问卷(SGRQ)评分的变化。结果:治疗后,两组FVC%、FEV1%均较治疗前明显升高,且治疗组显著高于对照组(P<0.05);两组CAT评分、症状评分、活动评分及总评分均较治疗前明显降低,且治疗组显著低于对照组(P<0.05)。两组并发症发生率无显著性差异(P>0.05)。结论:布地奈德福莫特罗粉吸入治疗肺癌合并COPD可有效改善患者的肺功能和生活质量。
OBJECTIVE: To evaluate the clinical efficacy of formoterol budesonide inhalation in the treatment of patients with lung cancer complicated with chronic obstructive pulmonary disease (COPD) and their impact on quality of life. Methods: Sixty-eight patients with lung cancer complicated with COPD admitted from January 2015 to December 2016 in our hospital were divided into treatment group and control group according to the random number table method, with 34 cases in each group. The control group was given conventional symptomatic treatment. The treatment group was treated with budesonide formoterol powder inhalation on the basis of the control group, twice a day for 3 months. The changes of FVC%, FEV1%, COPD and SGRQ were compared between the two groups before and after treatment . Results: After treatment, FVC% and FEV1% in both groups were significantly higher than those before treatment, and the treatment group was significantly higher than the control group (P <0.05); CAT score, symptom score, activity score and total score Before the treatment group was significantly lower than the control group (P <0.05). There was no significant difference in the incidence of complications between the two groups (P> 0.05). CONCLUSIONS: Inhaled budesonide formoterol powder for lung cancer with COPD can effectively improve lung function and quality of life of patients.